Royalty Payable	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable    The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its Opioid Overdose Reversal Treatment Product ("OORTP"). In exchange for this funding, the Company agreed to provide investors with interest in the OORTP Net Profit generated from NARCAN® sales by EBS into perpetuity. As of September 30, 2020 and December 31, 2019, the Company recorded a royalty payable of $2.0 million and $1.6 million, respectively.